Compare Charles River Laboratories Intl. Inc (CRL) vs HSBC Holdings plc (HSBC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs HSBC Holdings plc — how do they compare? Charles River Laboratories Intl. Inc trades at $297.28 (market cap $14.23B), while HSBC Holdings plc trades at $92.4 (market cap $311.92B). The key difference: HSBC Holdings plc is far larger — about 21.9× Charles River Laboratories Intl. Inc's market cap, and HSBC Holdings plc pays a 4.05% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and HSBC Holdings plc for 36 Days on average.
| CRL | HSBC | |
|---|---|---|
Market Cap | $14.23B | $311.92B |
Volume | 1,176,885 | 3,546,658 |
Sector | Health | Financials |
52-Week High | $310.77 | $107.86 |
52-Week Low | $149.93 | $65.67 |
Typical Hold Time | 33 Days | 36 Days |
Enterprise Value | $17.06B | $222.19B |
Dividend Yield | — | 4.05% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $300.30, down 1.53% on the day, with strong analyst support showing 73% buy ratings and a $305.50 consensus target. The stock maintains a bullish technical signal with support at $295 and resistance at $306. Recent earnings have consistently beaten expectations, though the company faces profitability challenges with negative net income margins and elevated valuation multiples.
While CRL shows promising growth initiatives including 5-7% revenue targets and $300M savings by 2030, investors face risks from negative profitability, high debt levels, and premium valuations. The stock's near-term catalyst will be Q3 2026 earnings against $2.97 EPS expectations, with technical positioning suggesting limited downside from current levels.
HSBC trades at $93.71, down 3.97% today, with a bearish technical signal from moving averages and oscillators. The stock shows solid fundamentals with a P/E of 13.23, net income margin of 34.54%, and recent earnings beats in two of the last three quarters. Recent developments include expansion in technology banking and wealth management services, while analyst consensus leans toward Hold with 52.38% of ratings.
The outlook remains mixed with strong profitability metrics offset by bearish technical indicators and negative net cash flow. Key opportunities include wealth management growth and strategic hires, while risks involve CFO transition and competitive pressures. The stock's valuation appears reasonable but requires monitoring of cash flow trends and execution on growth initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About HSBC Holdings plc
HSBC is one of the world's largest banking and financial services organizations. It serves customers worldwide through four global businesses: Retail, Commercial, Global Banking, and Private Banking.
Read more on HSBC →
